Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Change in Accured Expenses (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Change in Accured Expenses for 15 consecutive years, with $294000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 85.14% to $294000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 13.27% year-over-year, with the annual reading at $5.7 million for FY2025, 988.31% up from the prior year.
  • Change in Accured Expenses hit $294000.0 in Q4 2025 for Vistagen Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.7 million in Q3 2021 to a low of -$2.4 million in Q2 2025.
  • Historically, Change in Accured Expenses has averaged $560480.0 across 5 years, with a median of $434750.0 in 2023.
  • Biggest five-year swings in Change in Accured Expenses: surged 635.32% in 2024 and later tumbled 432.75% in 2025.
  • Year by year, Change in Accured Expenses stood at -$1.5 million in 2021, then grew by 3.38% to -$1.5 million in 2022, then skyrocketed by 118.4% to $269000.0 in 2023, then soared by 635.32% to $2.0 million in 2024, then plummeted by 85.14% to $294000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for VTGN at $294000.0 in Q4 2025, $3.2 million in Q3 2025, and -$2.4 million in Q2 2025.